Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
- Published In:
- Immunopharmacology and immunotoxicology, 37(4), 388-92 (2015)
- Authors:
- Jia, Zhiyang, Feng, Zihui, Tian, Rui(2), Wang, Qian, Wang, Linyu
- Database ID:
- RPEP-02673
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02673APA
Jia, Zhiyang; Feng, Zihui; Tian, Rui; Wang, Qian; Wang, Linyu. (2015). Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.. Immunopharmacology and immunotoxicology, 37(4), 388-92.
MLA
Jia, Zhiyang, et al. "Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.." Immunopharmacology and immunotoxicology, 2015.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin α1 plus routine treatment inhibit inflammatory reac..." RPEP-02673. Retrieved from https://rethinkpeptides.com/research/jia-2015-thymosin-1-plus-routine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.